Frankfurt am Main, December 18, 2015 -- Moody's Investors Service, (Moody's) has today downgraded the long-term senior unsecured ratings of AstraZeneca PLC and its subsidiary Zeneca Wilmington Inc. to A3/(P)A3 from A2/(P)A2. Concurrently Moody's has also downgraded the company's short-term rating to P-2 from P-1. The outlook on all ratings is stable.
Vollständigen Artikel bei Moodys lesen